Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3859 - Extracts of Cerbera manghas L. effectively inhibit the growth of glioblastoma cells and their stemloids

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cancer Biology

Tumour Site

Central Nervous System Malignancies

Presenters

Yun-Ju Lai

Citation

Annals of Oncology (2018) 29 (suppl_8): viii122-viii132. 10.1093/annonc/mdy273

Authors

Y. Lai, J. Tsai, W. Liu, H. Lam

Author affiliations

  • Department Of Life Science, National Taiwan Normal University, 11677 - Taipei/TW

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3859

Background

Glioblastoma multiforme (GBM) is the grade IV glioma and the most common adult primary brain tumor. It is notorious for its heterogeneity, invasiveness and resistance to chemo- and radiotherapies. These characteristics make it a highly recurrent malignant disease with poor prognosis. The potential new target for intervention in GBM is its cancer stem cells (GSCs).

Methods

To identify an improved treatment by targeting GSCs, we screened 400 botanical extracts for their effects on cytotoxicity and colony formation ability in GBM cell lines and tumorspheres.

Results

We identified the extracts of Cerbera manghas L. as being effective inhibitors of the growth and migration of GBM cell lines and its tumorspheres. We further demonstrated that neriifolin was one of the active principles. Neriifolin effectively inhibits the growth of CD133+-GBM tumorspheres and their colony formation. The extracts of Cerbera and neriifolin both reduced AKT activation and caused cell cycle G1 arrest while reducing the protein level of the stem cell marker Sox2. Furthermore, higher doses of these treatments induced apoptosis of tumorspheres. In the mouse xenotransplantation model, neriifolin inhibited the growth of CD133+-GBM tumorsphere-derived tumors in vivo.

Conclusions

In summary, neriifolin obtained from extracts of C. manghas may serve as a drug lead compound for GBM therapies.

Clinical trial identification

Legal entity responsible for the study

Department of life Science, National Taiwan Normal University.

Funding

Ministry of Science and Technology, Taiwan, ROC.

Editorial Acknowledgement

Louise T. Chow.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.